Richard A. Ward
AstraZeneca (United Kingdom)(GB)AstraZeneca (France)(FR)AstraZeneca (Singapore)(SG)AstraZeneca (Poland)(PL)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways, HER2/EGFR in Cancer Research, Synthesis and biological activity, Synthetic Organic Chemistry Methods
Most-Cited Works
- → AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer(2014)2,182 cited
- → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
- → Challenges and Opportunities in Cancer Drug Resistance(2020)419 cited
- → Structure-based design of targeted covalent inhibitors(2018)331 cited
- → Proteomic Analysis of Human Neutrophil Granules(2005)315 cited
- → Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase(2014)313 cited